Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (864)	5/12/1999 7:49:00 AM
From: smh	Read Replies (1) \| Respond to of 1073

DAK, This is nothing more than an observation from a lurker, but it seems like many of the threads I follow have been slowly drying up over the last few months. You are doing a good job of keeping them going. Wish I had something to contribute. Have a stack of annual reports but not enough time to dig into lately. Regards SMH

To: LLCF who wrote (864)	5/12/1999 2:02:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1073

David, Biotech has definitely had some good weeks recently, particularly in the face of weakness in the drug stocks. Definite stirrings in selected 2nd and 3rd tiers - I just haven't really figured out what the current definition of "selected" is yet. <g> Cancer-oriented biotechs have been pretty hot recently - maybe speculation ahead of ASCO. Last year, ASCO marked the top in these stocks. Let's hope history won't repeat itself. I still hold a little SNAP, but I'm not currently buying more. VRTX looks cheap to me - nice pipeline, an approved drug that I think will do better than the very low expectations for it, plenty of cash. AXPH is cheap but they've just announce a major shift in direction (to cancer) and they may just stay cheap until they provide some evidence of progress someplace. Peter